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TrafﬁckingThe appearance of heme, an organic ring surrounding an iron atom, in evolution forever changed the efﬁcien-
cy with which organisms were able to generate energy, utilize gasses and catalyze numerous reactions. Be-
cause of this, heme has become a near ubiquitous compound among living organisms. In this review we
have attempted to assess the current state of heme synthesis and trafﬁcking with a goal of identifying crucial
missing information, and propose hypotheses related to trafﬁcking that may generate discussion and re-
search. The possibilities of spatially organized supramolecular enzyme complexes and organelle structures
that facilitate efﬁcient heme synthesis and subsequent trafﬁcking are discussed and evaluated. Recently iden-
tiﬁed players in heme transport and trafﬁcking are reviewed and placed in an organismal context. Addition-
ally, older, well established data are reexamined in light of more recent studies on cellular organization and
data available from newer model organisms. This article is part of a Special Issue entitled: Cell Biology of
Metals.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Heme is an iron containing prosthetic group found in many pro-
teins and plays a critical role in various biological processes such as
electron transport, gas synthesis and sensing, xenobiotic detoxiﬁca-
tion, signal transduction, microRNA processing, and circadian clock
control [1–4]. In metazoans, heme is synthesized via a conserved
eight-step biosynthetic pathway. The last step of heme biosynthesis,
the insertion of ferrous iron into the protoporphyrin IX ring, occurs
inside the mitochondrial matrix. However, target hemoproteins
such as guanylyl cyclases, catalases, cytochrome P450 and certain
transcription factors are present in extra-mitochondrial compart-
ments including the cytoplasm, peroxisomes, the secretory pathway
and the nucleus [5–8]. As an iron-containing amphipathic porphyrin,
free heme can catalyze the production of reactive oxygen species and
intercalate into lipid bilayers [9,10]. Thus, heme is unlikely to diffuse
freely within the cell but instead, speciﬁc molecules and pathways
must exist to facilitate heme delivery to distinct cellular destinations.
Although the enzymes for heme biosynthesis and its regulation
are well-characterized in metazoans, signiﬁcant knowledge gaps per-
sist [6,11]. Even less well deﬁned are the pathways for transport andiology of Metals.
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rights reserved.trafﬁcking of heme and its intermediates. A comprehensive survey of
the possible mechanisms for heme trafﬁcking based upon known
pathways for membrane trafﬁcking and interorganellar transfer of
metabolites has been covered in detail elsewhere [6–8]. The current
review highlights scientiﬁc gaps in our understanding of heme syn-
thesis and trafﬁcking in metazoans and offers plausible models which
can be experimentally tested. Given the signiﬁcant differences in tetra-
pyrrole metabolism in photosynthetic organisms, readers are referred
to insightful, comprehensive reviews elsewhere [11–15].
2. Heme biosynthesis
2.1. Aminolevulinate synthesis
The ﬁrst committed step in heme biosynthesis is the formation of
5-aminolevulinate (ALA) [14,16–19]. In the metazoa the enzyme ALA
synthase (ALAS) (E.C. 2.3.1.37) catalyzes the condensation of glycine
with succinyl CoA to form ALA and CO2. ALAS is a homodimeric, pyri-
doxal phosphate-containing enzyme that is a member of the large and
well-characterized α-oxoamine synthase family. At present only the
crystal structure of ALAS from the bacterium Rhodobacter capsulatus
has been determined [20], but it is clear that the mature eukaryotic
ALAS is highly similar to the bacterial enzyme except that it possesses
an additional carboxyl-terminal sequence of approximately 25 resi-
dues. Much is known about the mammalian enzyme from kinetic and
site-directed mutagenesis studies [17]. In vertebrates, two isozymes of
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ALAS-E) and the other expressed in all other cell types (ALAS-1 or
ALAS-N). The genes for ALAS, as for all heme biosynthetic enzymes,
are nuclear, although the ﬁnal destination for ALAS is the mitochondri-
on. Both ALAS-1 and -2 possess mitochondrial targeting sequences that
are cleaved as part of the translocation of ALAS into the mitochondrial
matrix [21–23].
2.2. Synthesis of the monopyrrole, porphobilinogen
Once ALA is produced by ALAS it is exported out of the mitochon-
drial matrix (see below) to reach the second pathway enzyme,
porphobilinogen synthase (PBGS) (E.C. 4.2.1.24) (previously named
ALA dehydratase) (Fig. 1) [24]. This enzyme catalyzes the condensa-
tion of twomolecules of ALA to form onemolecule of themonopyrrole
PBG. The cytoplasmically located PBGS homo-octomer can best be
considered a tetramer of homodimers with one divalent metal atom
per subunit [16,24]. In humans and yeast, this metal is zinc while in
bacteria one may also ﬁndmagnesium. Four metal atoms are essential
for catalysis and four are involved in stabilization of tertiary structure.
These zinc ions may be replaced by lead in lead poisoning resulting in
an inactive enzyme. The protein has been crystallized from multiple
sources and kinetically characterized (see [14,25]). The Jaffe group
has shown that PBGS exists in alternate quaternary structures
namedmorpheeins [26]. Themorpheeins represent a dynamic change
in oligomerization of PBGS between the high activity octomer and a
low activity hexamer. This change in quaternary structure is the
basis of allosteric regulation of PBGS. However, given that ALAS is con-
sidered rate-limiting to heme synthesis, the role of allosteric regula-
tion at PBGS is something of an enigma.
2.3. Assembly of the linear tetrapyrrole, hydroxymethylbilane
Following formation of PBG, the enzyme hydroxymethylbilane
synthase (HMBS, previously called PBG deaminase or PBGD) (E.C.
2.5.1.61) catalyzes the head to tail synthesis of four PBG moleculesFig. 1. The mammalian heme biosynthetic pathway. The diagram presents the enzymatic ste
the mitochondrion are enclosed in the dashed box and those outside the box are present in t
enzyme listed. Synthesis of ALA from glycine and succinyl CoA, which is the ﬁrst committeto form the linear tetrapyrrole hydroxymethylbilane (HMB) and re-
leases four molecules of ammonium [24]. Partly because a decrease
in HMBS activity leads to the human disease acute intermittent por-
phyria (AIP) [27,28], this enzyme became the early focus of much
attention by researchers. HMBS has been puriﬁed from a variety of
sources and the crystal structures of the Escherichia coli [29] and
human [30] enzymes have been determined. The cytoplasmically-
located monomer is synthesized as an apoprotein that in its ﬁrst com-
plete catalytic cycle synthesizes a covalently-bound hexameric linear
polypyrrole. From this the distal linear tetrapyrrole HMB is cleaved
resulting in formation of the holoenzyme HMBS with a covalently
bound dipyrromethane which serves as a cofactor for future turn-
overs and the product HMB. HMB is chemically reactive and will
spontaneously cyclize to form uroporphyrinogen I in the absence of
the next pathway enzyme. Uroporphyrinogen I cannot be converted
into protoporphyrin IX.
2.4. Cyclization of the tetrapyrrole to form uroporphyrinogen
Conversion of HMB to the physiological uroporphyrinogen III iso-
mer requires the action of uroporphyrinogen synthase (UROS) (E.C.
4.2.1.75) [24]. The reaction which is catalyzed without a cofactor is
the “ﬂipping” or inversion of the ﬁnal, or D, ring of HMB followed
by cyclization to yield the III isomer of uroporphyrinogen. UROS is a
monomeric protein whose structure has been determined for both
human [31] and Thermus thermophilus [32]. Its structure is unusual
since it is composed of two distinct domains connected by a ﬂexible
linker region. Crystal structures have been obtained for a variety of
domain orientations suggesting that the molecule is highly ﬂexible
in solution [31,32].
2.5. Decarboxylation of uroporphyrinogen
The ﬁnal cytoplasmic enzyme in the pathway is uroporphyrinogen
decarboxylase (UROD) (E.C. 4.1.1.37) [33]. This homodimeric enzyme
has been crystallized [34] and its catalytic mechanism is well studiedps and structures of intermediates in the pathway from ALA to heme. Steps that occur in
he cytosol. Regions highlighted in red show the site of chemical change catalyzed by the
d step and occurs in the mitochondrion, is not shown. Abbreviations are as in the text.
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contains no cofactors or metal ions. UROD catalyzes the decarboxyl-
ation of the four pyrrole acetic acid side chains of uroporphyrinogen
to yield the four methyl pyrrole side chains of coproporphyrinogen
and four molecules of CO2. UROD will utilize both uroporphyrinogen
I and III and in the presence of high concentrations of substrate,
UROD will decarboxylate randomly [24]. However, it is believed that
in situ the reaction starts with the decarboxylation of the D ring ace-
tate and proceeds sequentially in a clockwise fashion (i.e. D, A, B, C)
[34,35].2.6. Formation of the vinyl groups of protoporphyrinogen IX
Coproporphyrinogen III produced by UROD is transported into the
mitochondrial intermembrane space where the antepenultimate en-
zyme coproporphyrinogen oxidase (CPOX) (E.C. 1.3.3.3) is located
[36,37]. This protein is synthesized in the cytoplasmwith an unusually
long (~120 amino acid) mitochondrial leader sequence that targets it
to the innermembrane space [21]. Themature protein is a homodimer
without bound cofactor. The structures of both human [38] and yeast
(which is a cytoplasmic protein) [39] CPOX have been solved andwere
found to possess unique folds. The reaction catalyzed is an unusual ox-
idative decarboxylation of the A and B ring propionates to yield the
vinyl groups of protoporphyrinogen IX. CPOX will utilize only the
coproporphyrinogen III isomer and proceeds in a stepwise fashion
that requires two molecules of molecular oxygen and generates two
molecules of CO2. The reaction catalyzed by CPOX has been extensive-
ly studied both experimentally and in silico, but at present no deﬁni-
tive mechanism has been identiﬁed [40,41].2.7. Oxidation of the porphyrinogen to protoporphyrin IX
The penultimate step is the oxidation of protoporphyrinogen IX to
protoporphyrin IX. This is catalyzed by protoporphyrinogen oxidase
(PPOX) (E.C. 1.3.3.4) which requires three molecules of molecular ox-
ygen and generates three molecules of hydrogen peroxide [36,37].
Crystal structures of the plant [42], bacterial [43,44], and human [45]
enzymes have been determined and show that the protein is a homo-
dimer with one noncovalently bound FAD per subunit. PPOX is syn-
thesized in the cytoplasm in its mature size and is translocated to the
outer surface of the inner mitochondrial membrane via a mechanism
that requires an internal mitochondrial targeting sequence [21,46,47].
Interestingly, the active site is proposed to be situated in the middle of
a tunnel that passes through the protein.2.8. Insertion of iron to form protoheme IX
The terminal step of heme synthesis is the insertion of ferrous iron
into the protoporphyrinmacrocycle to produce protoheme IX (heme).
This is catalyzed by the enzyme ferrochelatase (FECH) (E.C. 4.99.1.1)
[48]. In metazoans this enzyme is synthesized in the cytoplasm as a
preprotein and is translocated to the mitochondrial matrix where it
is associated with the inner mitochondrial membrane. The mature,
processed protein is a homodimer with each subunit possessing a
[2Fe–2S] cluster [49]. Similar [2Fe–2S] clusters are not found in plant
FECHs, but are found in some bacteria [48,50]. There is no evidence
to suggest that the cluster participates directly in catalysis, but recent
studies suggest that it may serve as a sensor of mitochondrial matrix
redox or membrane potential (D. Shah et al., unpublished data). The
crystal structures of human FECH with and without substrate and
product have been determined and it has been shown that the mole-
cule undergoes considerable active site remodeling during catalysis
[18,51].2.9. Synthesis and localization of metazoan heme biosynthetic enzymes
Enzymes of heme biosynthesis are nuclear encoded and cytoplas-
mically synthesized. The overall reaction to synthesize heme in meta-
zoan cells is: 8 glycine+8 succinyl CoA+5 O2+Fe2+→Heme+8
CoA+4 NH4+14 CO2+3 H2O2+2H++11 H2O. Of the products,
8 CoA, 8 CO2, 2H+ and heme are generated in the mitochondrial ma-
trix, and 2 CO2+3 H2O2+and 2 H2O are generated in the mitochon-
drial inner membrane space. All remaining products are cytosolic. As
noted above, ﬁve pathway proteins possess either organic co-factors
or essential metals. To date no pathway enzymes have been shown
to be glycosylated and only mouse liver FECH has been reported to
be phosphorylated [52], albeit on residues that appear to be in inac-
cessible sites within the protein. Interestingly these investigators
also reported that phosphorylated FECH is located on the mitochon-
drial outer membrane, something never reported by any other group
previously.
Regulation of the pathway is tissue and cell speciﬁc, subject tomod-
ulation bymyriad developmental and environmental pressures through
diverse transcriptional factors, and is beyond the scope of the current
review [18,53,54]. In general, however, synthesis of the ﬁrst committed
intermediate, ALA, is considered rate-limiting. Among red blood cell
containing metazoans there are clear distinctions between regulation
of heme synthesis in non-erythroid cells (so-called housekeeping
heme synthesis) and in differentiating erythroid precursor cells. The
housekeeping ALAS-1 gene is regulated by diverse factors frequently as-
sociated with xenobiotic, hormone and drugmetabolism, and is subject
to tissue-speciﬁc regulation [53,55]. ALAS-1 has an estimated half-life of
only a few hours andmay be signiﬁcantly induced in some cells [19,56].
ALAS-1 is present in erythroid precursor cells before they begin ery-
throid differentiation, but the gene is turned off when ALAS-2 is turned
on as these cells begin to synthesize heme for hemoglobin. Thus ALAS-1
cannot substitute for a deﬁciency of ALAS-2 [57,58].
ALAS-2 is transcriptionally regulated by erythroid-speciﬁc factors
such as GATA-1 and possesses an iron regulatory element (IRE) locat-
ed in the mRNA 5′ untranslated region that allows for translational
regulation by cellular iron concentration [55,59,60]. As with similarly
regulated systems, such as for ferritin synthesis, the IRE binds the
iron-free form of the iron regulatory protein (IRP) thereby preventing
translation of the ALAS-2 message when cellular iron concentrations
are insufﬁcient for optimal heme synthesis. Thus, maximal ALAS-2
activity requires gene induction by erythroid-speciﬁc transcription
factors as well as sufﬁcient cellular iron levels to support heme syn-
thesis. Studies by Schranzhofer et al. [61] with differentiating erythro-
blasts demonstrated that ALAS-2 translational regulation becomes
“uncoupled” from that of other IRE-regulated proteins such as trans-
ferrin receptors (which are increased, not decreased during erythro-
poiesis) and ferritin (whose protein levels do not increase). This is
reasonable during the later accelerated hemoglobinization phase of
erythropoiesis since under “standard” IRE–IRP regulation elevated
iron would diminish transferrin receptor expression and increase
ferritin synthesis, both of which would limit iron availability for
heme synthesis. Additionally it was postulated that during maximal
hemoglobinization, ALAS-2 mRNA increases disproportionately to
IRP synthesis thus circumventing the IRE–IRP regulatory mechanism.
It was suggested that the “kiss and run” hypothesis [62], which pro-
poses direct vesicle mediated transfer of iron to mitochondria, may
offer a possible means to circumvent this potential problem [63].
In this hypothesis, during terminal erythropoiesis, vesicular iron ac-
quired by receptor mediated endocytosis is targeted directly to the
mitochondrion, thereby bypassing the cytosolic iron pool and the
IRE–IRP system [63].
Multiple studies and reviews have presented data suggesting that
pathway enzymes after ALAS are in excess, although relative enzyme
amounts vary considerably [1,28,53]. However, these calculations are
based upon in vitro assays of individual enzymes under what are
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cell conditions. There are no comprehensive studies that examine the
induction of biosynthetic pathway enzymes other than ALAS-1 in
nontransformed nonerythroid cells, but the fact that all of the pathway
genes possess diverse transcription factor binding sites is compatible
with regulation at multiple sites [57,64–72]. Indeed, in cancer cells it
is clear that at least CPOX and FECH are up and down regulated, respec-
tively, and this is the basis for the effectiveness of photodynamic ther-
apy [73,74]. It has been demonstrated that there is up-regulation of all
pathway enzymes during erythroid differentiation (see [73]). Even so,
current dogma relegates pathway regulation during erythropoiesis to
ALAS-2 alone [18,54]. Recent data may cause a reevaluation of this
model since it has been discovered that a mutation in the carboxyl-
terminus of ALAS-2, which results in a hyperactive enzyme, causes an
accumulation of free protoporphyrin as is found in the disease erythro-
poietic protoporphyria (EPP) [75]. The name currently given to this dis-
order is X-linked protoporphyria (XLPP) to reﬂect the X chromosome
location of ALAS-2. This disorder is, thus, similar, but not identical, to
that observed when ALAS-2 is overproduced in Irp2−/− mice [76].
The observation of protoporphyrin accumulation in XLPP is particularly
interesting since levels of FECH are generally assumed to be present in
considerable excess in the cell. Indeed, normal EPP occurs only when
FECH levels drop to approximately one-fourth of normal [77]. This sug-
gests that either the erythroid pathway is designed so that the amount
of FECH (or iron transport mechanisms for heme synthesis) available is
normally three- to four-fold above the maximum possible levels of
ALAS-2, or that additional regulatory steps or limiting mechanisms
exist at the end of the pathway that we currently do not recognize or
understand.
For both ALAS-1 and ALAS-2 one ﬁnds alternativemRNA splice var-
iants. For ALAS-1 two known splice variants occur in the untranslated
region of exon 1 [78]. These variants possess altered sensitivity to
heme-mediated decay of the message. For human ALAS-2 one splice
variant has been described in which exon 4 is absent [79]. This variant
represents 35–45% of total ALAS-2 mRNA in the cell and encodes a
protein with slightly reduced activity. This variant ALAS-2 is trans-
located into the mitochondrial matrix where it was shown to interact
with succinyl CoA synthetase (SUCLG1), just as the full length enzyme
does, and contributes to erythroid heme synthesis. Interestingly, both
ALAS-1 and -2 possess three heme regulatory motifs (HRMs) com-
posed of a canonical Cys-Pro sequence [62]. Two HRMs are found in
the targeting leader sequence and the third is near the amino terminus
of the mature processed ALAS [21]. While such motifs have recently
been shown to serve as a redox sensitive switch for heme oxygenase-
2 [51], there is no evidence to suggest such a role for these motifs in
ALAS. Indeed, evidence from multiple groups has shown that heme
binds to the ALAS HRMs in vitro [22] and in vivo [21,23], and a series
of mutagenesis experiments clearly demonstrated the signiﬁcance of
all three ALAS HRMs in the heme responsive translocation of the
protein into mitochondria in vivo [21]. While such heme regulation of
apoprotein translocation into the mitochondria of nonerythroid cells
can easily be rationalized, a similar occurrence in differentiating ery-
throid cells where massive quantities of heme are being synthesized
in a relatively short period of time is less easily justiﬁed. Several signif-
icant pieces of information that would address this issue are lacking.
Among these is an identiﬁcation of the fate of both cytoplasmic ALAS
precursor apoprotein and any heme bound to the HRMs. The possibility
that the HRM-containing leader peptide or apoprotein HRM serves as a
heme chaperone for globin assembly is intriguing, but no data exist to
support or rule out this proposition.
While two distinct genes on separate chromosomes exist for ALAS-1
and -2, only single genes exist for the remaining pathway enzymes.
However, for PBGS, HMBS, UROS and FECH, housekeeping vs. erythroid
speciﬁc promoter regions drive expression that leads to tissue-speciﬁc
alternate mRNA splicing. Only the HMBS alternate splice variants, how-
ever, give rise to isoenzymes of HMBS with alternative amino-terminalsegments [66]. Here the mRNA of the erythroid form of HMBS skips
exon 1 and starts with the noncoding exon 2. The translation start site
employed for the erythroid HMBS is in exon 3. The housekeeping
HMBS mRNA starts with exon 1, which contains an internal start site
and coding region, and skips the non-coding exon 2. The result is that
the housekeeping HMBS has an additional 17 amino acid residues at
the amino terminus that are lacking in the erythroid form. Human
PBGS possesses two non-coding exons, 1A and 1B [67]. The translational
start site for housekeeping PBGSmRNA is exon 1Awhile erythroid PBGS
mRNA starts in exon 1B. Thus, an additional 5′ untranslated region is
present in the mRNA for the housekeeping variant that is lacking in
the erythroid splice variant. Since these variants are in the noncoding
region, the housekeeping and erythroid forms of the PBGS enzyme are
identical. Splice variants also exist for UROS [64]. The gene for UROS
possesses spatially distinct erythroid and housekeeping promoters
with the erythroid promoter elements located in the intron between
exons 1 and 2. This promoter drives transcription from an initiation
site in exon 2. The housekeeping promoter region is present upstream
of exon 1 and drives transcription from an initiation site in exon 1. How-
ever, since exon 1 is non-coding, both housekeeping and erythroid
UROS proteins are identical. For mouse FECH there appears to be an
alternate splice site that gives rise to additional 3′ untranslated nucleo-
tides [80].
While the existence of splice variants is not a new observation, any
experimentally supported rationale for a physiological role for these
variants is lacking. However, recent studies on the role of RNA in the
spatial regulation of protein synthesis [81] and/or in stabilization of
multiprotein complexes [82] raise the intriguing possibility that the
alternative splicing for mammalian housekeeping vs. erythroid forms
of PBGS, HMBS and UROS is not random, but may serve for sequestra-
tion of mRNA primed for function.
It has been proposed that during the course of normal erythropoi-
esis, heme synthesis in developing erythroid cells overproduces heme
to an extent that it is toxic to the cell unless it is exported by the plas-
ma membrane heme transporter Feline Leukemia Virus subtype C
Receptor (FLVCR) (see below) [83]. While it is clear that disabling
mutations in FLVCR result in cell death, presumably due to the toxic
effects of excessive heme, it seems counterintuitive that evolution
would have designed such intricate regulatory mechanisms for ery-
throid heme synthesis (i.e., IRE–IRP, erythroid speciﬁc transcription
factors and complex iron supply regulatory schemes) that would per-
mit excessive synthesis of heme necessitating heme export. Indeed,
given the “cost” of heme synthesis, it seems more likely that the “ex-
cessive” heme produced is a planned synthesis of heme by erythroid
cells (which must be considered the ultimate heme synthesizing fac-
tories in the body) for orderly export and transit to other organs and
cells whose heme synthesizing capabilities may be physiologically
limited. The presence of speciﬁc heme carriers, such as hemopexin
[84], and the observation that exogenous administration of heme to
human porphyria patients downregulates heme synthesis, and is sub-
sequently utilized for hemoproteins by the patient receiving the infu-
sion [27], provide support for this hypothesis.
2.10. Possible role of supramolecular protein assemblies in heme synthesis
The chemical intermediates in tetrapyrrole synthesis are relatively
reactive and can be cytotoxic. The physiological proof of this state-
ment is amply demonstrated by the fact that a deﬁciency in any one
of the pathway enzymes results in a clinically distinct disease in ani-
mals [28,53,77], and inhibition of some later steps can result in photo-
induced death of plants or microorganisms. Other than a defect in
ALAS-2 which results in X-linked sideroblastic anemia, the clinical
manifestations of these disorders, named porphyrias, are generally
not anemia, but result from the accumulation of pathway intermedi-
ates upstream from the genetic block. In the case of early pathway en-
zyme deﬁciencies, the disorders are neurological in nature and are
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steps after the synthesis of the ﬁrst tetrapyrrole, the most profound
symptoms of the disorders are cutaneous in nature due to the chem-
ical and photo-reactivity of the tetrapyrrole intermediate. These dis-
eases and their molecular basis have been well studied and frequently
reviewed by others (see [27,28,53,77]).
Of signiﬁcance to the current review is the intracellular distribu-
tion of heme synthesis pathway enzymes. The ﬁrst and last three en-
zymes are cytoplasmically synthesized and translocated into the
mitochondrion while PBGS, HMBS, UROS and UROD are all located in
the cytoplasm [16,24]. As discussed above, the ﬁrst and last enzymes,
ALAS [17,21–23] and FECH [37,48], are translocated to the mitochon-
drial matrix where their pre-proteins are proteolytically processed
and assembled with appropriate cofactors while CPOX [85] and PPOX
[86] are both homodimers located in the inner mitochondrial mem-
brane space. The translocation of all four mitochondrially-located en-
zymes has been studied to varying extents, but only ALAS has been
found to have any identiﬁable heme-responsive translocation regu-
latory motifs [21] and no experimental data exist to suggest that
there is coordinate regulation of either synthesis or translocation of
these enzymes.
Given the reactivity of the pathway intermediates it is highly un-
likely that the intracellular concentrations of substrate or products at-
tain the μM concentrations of the measured enzyme Kms. Thus, it is
reasonable to assume that “free intermediates” do not exist in the
cell although various porphyrin intermediates are routinely found in
the extracellularmediumofmammals. This topicwas ﬁrst approached
experimentally in the 1980s when data were presented in support of
the hypothesis that the terminal three pathway enzymes, which are
allmitochondrialmembrane-associated, form at least a transient com-
plex to facilitate the transfer of intermediates [37,86,87]. Biochemical
data clearly demonstrated that while obligate, tight substrate channel-
ing such as occurs in tryptophan synthesis does not exist, under nor-
mal circumstances equilibration of products/substrates with the bulk
medium does not occur. Data gleaned from PPOX and FECH crystal
structures provides good support for possible interactions [36,51].
Other than data for the terminal, membrane-associated enzymes,
there exists little experimental evidence to support multienzyme
complexes of earlier pathway enzymes. For the ﬁrst step, an interac-
tion of ALAS-2 with SUCLG1 on the inner mitochondrial membrane
has been demonstrated by two groups [79,88]. With the recent identi-
ﬁcation of SLC25A38 as the putative glycine/ALA transporter [89], it is
reasonable to anticipate the existence of transient complexes between
ALAS, SUCLG1, and SLC25A38 on the mitochondrial inner membrane
(Fig. 2). The possibility for a stable, rigid complex for these and most
other heme synthesis enzymes seems unlikely given that they possess
active site pockets with a single entrance/exit (see [14]). The necessityFig. 2. Proposed model for components involved in heme synthesis. Details are discussed in
Components that are currently unidentiﬁed experimentally are denoted with “?”. Abbreviafor substrate(s) and product(s) to enter and exit via a single route
would require movement of one enzyme between donor and acceptor
molecules in the complex, much as cytochrome c physically cycles be-
tween electron donors and acceptors. The only enzyme for which this
may not be the case is PPOX which appears to have a channel through
the protein with the active site located within this feature [42,43,45].
For the synthesis of uroporphyrinogen III from PBG, it has long
been thought that close proximity of HMBS and UROS would be prob-
able given the chemical reactivity of the linear tetrapyrrolic interme-
diate, hydroxymethylbilane. Unfortunately at present no data exist to
support the presence of a multienzyme complex involving PBGS and
HMBS. Given that ALA must be exported out and coproporphyrinogen
imported into the mitochondria, logic would suggest that not only
PBGS and HMBS, but also UROS and UROD exist in a supramolecular
complex that is spatially close to the mitochondrion (Fig. 2). To date,
high resolutionmicroscopic studies identifying the intracellular distri-
bution of these enzymes are lacking. Approaches that rely upon cell
disruption and physical isolation of complexes or in vitro reconstitu-
tion of complexes from isolated components assume a strength of
protein–protein interaction in solution that may not exist and may
not be necessary in the highly concentrated cytosolic milieu. One in-
triguing possibility is that PBGS, which forms a large complex best
categorized as a tetramer of homodimers, could, because of its size,
serve as a scaffold for a multienzyme complex. The observation that
PBGS can also assume a hexameric form [14,26] may hint at its plastic
role as a supramolecular assembly nucleation site. Resolution of these
issueswill requiremasterful research, but the resultswill be illuminating.
The presence and nature of multienzyme complexes involving
the terminal three membrane-associated enzymes is considerably ad-
vanced over what is known, or not known, about the earlier pathway
enzymes, but is still extremely rudimentary. Little is known about
possible interactions between CPOX and PPOX other than substrate
channeling experiments [87]. However, because of spatial and chem-
ical arguments, the possibility for interaction seems highly likely.
Radiolabeling experiments employing isolated mitochondrial frag-
ments clearly support transient interactions in situ, although reconsti-
tution of this process with puriﬁed components was not accomplished,
which suggests that additional participants other than just CPOX, PPOX
and FECH are required. In silico structural studies show that an interac-
tion across the inner mitochondrial membrane to transport protopor-
phyrin from PPOX to FECH is feasible and highly likely [42] (Fig. 3).
Interestingly, in the docked PPOX–FECH complex, the opening of
the active site tunnels of the PPOX dimer not only coincides with the
position of the openings to the active site pockets of the dimeric
FECH, but is also spatially juxtaposed to surface-bound porphyrin
molecules observed in some FECH crystal structures [18,90,91]. The
observation that binding of substrate and product induces changes inthe text and where speciﬁc data exist for a particular component, its name is shown.
tions and conventions are given in the text.
Fig. 3. Cartoon of proposed interaction between protoporphyrinogen oxidase (PPOX) and FECH across the inner mitochondrial membrane. The initial PPOX–FECH docking model
was published by Koch et al. [42] for plant PPOX and human FECH. The current model was derived from PDB ﬁles 3NKS (PPOX) and 2QD1 (FECH). FECH is colored green and PPOX is
colored violet. Porphyrin atoms are depicted as red colored solid spheres and the PPOX inhibitor is shown in solid black. Phospholipids are presented as sticks that are colored
wheat. Of note is that the crystal structures of FECH with bound porphyrin possess one protoporphyrin bound in the active site and a second one associated with the outer edge
of the active site lip. This is proposed to be the entry route of porphyrin into the active site pocket [18,90]. It is proposed that FECH and PPOX interact transiently across the mem-
brane to facilitate transfer of protoporphyrin to FECH. Following this transfer FECH undergoes spatial alterations that are proposed to lower the afﬁnity between FECH and PPOX so
that their interaction ceases thereby allowing FECH to interact with MTF1 and later a heme accepting protein.
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pocket opening of FECH [18,51] provides an explanation for how
PPOX and post-catalytic heme-accepting proteins recognize the appro-
priate form of FECH with which to interact. Given the need to acquire
coproporphyrinogen from the cytosol and movement of at least some
heme out of the mitochondrion, the existence of a complex of an
outer membrane coproporphyrinogen transporter, CPOX, PPOX, the
inner membrane iron transporter mitoferrin (Mtf1) [92], FECH and a
heme chaperone/outer membrane heme transporter at a mitoﬁlin-
mediated junction between outer and inner mitochondrial membranes
[47] is an intriguing possibility.
Three signiﬁcant issues remain unanswered: i) transport of
coproporphyrinogen into the mitochondrion, ii) mitochondrial supply
of iron for heme synthesis, and iii) transport of heme away from its
site of synthesis. With regard to transport of coproporphyrinogen III a
series of studies proposes that ABCB6, amitochondrial outer membrane
ATP-dependent transporter, is responsible for coproporphyrinogen
transport (see below) [93,94]. At present, however, this claim must be
viewedwith skepticism since only the transport of the fully conjugated,
planar macrocycle coproporphyrin, not the physiologically relevant
non-planar coproporphyrinogen, has ever been experimentally demon-
strated. However, given that ABCB6 has been observed to be one of a
relatively few genes induced at high levels during erythropoiesis [95],
it seems likely that it plays some role in erythropoiesis. Given the size
of coproporphyrinogen, the possibility that it transits the outer mem-
brane via a porin rather than a speciﬁc transporter cannot be ruled
out by current data.
Although the coordinate regulation of tetrapyrrole synthesis and
iron metabolism must exist to prevent their inappropriate accumula-
tion, there have been limited studies that address this issue at either
the genetic or molecular level. The role of the iron responsive element
system [45] and the cellular machinery for iron sulfur cluster assem-
bly has garnered signiﬁcant interest [96], and our knowledge of
whole body iron trafﬁcking is relatively mature [97]. However, only
recently has there been signiﬁcant advancement in identifying partic-
ipants essential to the iron supply for heme synthesis. This came with
the identiﬁcation of Mtf1 as the mitochondrial inner membrane irontransporter that supplies iron to FECH for heme synthesis [92]. Mtf1
is responsible for iron transport for heme synthesis during erythro-
poiesis, but the presence of another inner membrane transport pro-
tein, Abcb10, is required to stabilize Mtf1 [98]. The exact role that
Abcb10 plays has yet to be elucidated. Mtf1 has been found to form
a complex with FECH which might make possible a direct transfer
of transported ferrous iron for heme synthesis to FECH (Fig. 4) [98].
However, the actual site of iron entry for FECH remains undeﬁned
experimentally. One model proposes that mammalian FECH acquires
iron fromMtf1 or frataxin via the extended π-helix of FECH described
by Medlock et al. [91] and enters the active site via the main “mouth”
[99,100]. However, this model is based upon the structure of a single
monomer of FECH, not the physiologically signiﬁcant homodimer,
and the putative membrane binding surface in the model is, in fact,
the dimer interface. The crystal structures of dimeric human FECH
are consistent with a spatial orientation where the π-helix unwinds
into the membrane and not back up into the matrix. All available
data suggest that the helix extension is related to heme release and
in the absence of product there is nothing to stabilize the extended
helix. Additionally the simultaneous exit of heme and entrance of
iron via the same path are not supported by structural or kinetic stud-
ies [101,102]. Alternatively, structural and site directed mutagenesis
data obtained for human FECH along with its orientation relative to
the inner membrane are all consistent with iron entering the active
site of FECH via a solvent-ﬁlled channel whose entrance is on the
rear of the enzyme. It will be of interest to learn the molecular details
of this process and how it is regulated.
Transit of heme away from its site of synthesis remains an
unexplored territory. In vitro, the release of heme from the enzyme
post-metallation is the rate-limiting step [102]. This probably reﬂects
the absence of the native heme acceptor in a cell-free assay. Given
that heme is utilized throughout the cell in a variety of compart-
ments, it is clear that multiple and speciﬁc heme chaperones exist.
For transit from the mitochondrion to other membranous compart-
ments it appears likely that transfer occurs at direct contact points
rather than by diffusion through the cytoplasm [5,103], but even
that requires ﬁrst moving heme from FECH to the site of transfer
Fig. 4.Model of FECH andmitoferrin in the inner mitochondrial membrane. Human FECH is shown as a cartoon colored green with bound protoporphyrin in red spheres. A structure
of mitoferrin 1 is currently not available, but it will be highly homologous to the structure of another inner mitochondrial solute transporter, the ATP/ADP transporter, whose struc-
ture has been solved [246] and is shown as a cartoon in red. Both proteins are oriented in a phospholipid bilayer (wheat colored). No structure of ABCB10 is available and the struc-
tures of known ABC transporters are so diverse as to make estimates of a structure model of ABCB10 not possible. The model is shown to demonstrate that interactions between
FECH and MTF1 are possible given the relative sizes and spatial orientations in the membrane.
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heme from FECH and whether there is a single unique protein that
interacts with FECH or multiple pathway-speciﬁc proteins. Given its
location on the inner membrane, it would seem that for respiratory
cytochrome maturation direct transfer from FECH to cytochrome as-
sembly machinery is possible although deﬁnitive data are still lacking.
For cytoplasmic hemoproteins, including hemoglobin and myoglobin,
there are no identiﬁed players. Putative heme/porphyrin binding/
carrier proteins have been suggested and even biochemically charac-
terized [65,104], but none of these is supported by data as in vivo par-
ticipants in heme trafﬁcking (see below).
3. Heme transport and trafﬁcking
3.1. Heme transport in yeast
Heme uptake molecules have been identiﬁed in the pathogenic
yeast Candida albicans. Weissman et al. ﬁrst revealed that C. albicans
can utilize heme and hemoglobin through a pathway that is distinct
from iron uptake pathways [105]. Heme uptake in C. albicans exhibits
a rapid initial binding phase followed by a slower uptake phase [106].
It was subsequently discovered by a genome-wide screen that Rbt51
and Rbt5 are involved in hemeuptake in C. albicans [107]. RBT5 is highly
induced by iron limitation and its deletion in C. albicans impairs the uti-
lization of heme. Both Rbt51 and Rbt5 are glycosylphosphatidylinositol
(GPI)-anchored proteins mainly localized to the plasma membrane,
suggesting that they might function as receptors for heme and hemo-
globin [108]. After being taken upbyRbt5/Rbt51, hemeand hemoglobin
are delivered to the vacuole through an endocytosis-mediated pathway
[108]. Heme is then degraded by HO. The heme oxygenase enzyme
CaHMX1 of C. albicans was identiﬁed and characterized both in vivo
and in vitro [106,109]. The expression of CaHMX1 is positively regulat-
ed by heme and hemoglobin [110].
In contrast to fungal pathogens, the budding yeast Saccharomyces
cerevisiae utilizes exogenous heme very poorly. This indicates that
S. cerevisiae lacks high-afﬁnity heme transport systems. However,
under conditions of heme starvation or hypoxia, an energy-dependent
pathway for heme uptake has been detected [111]. Protoporphyrin up-
take gene 1 (PUG1)was identiﬁed bymicroarray analysis on S. cerevisiae
grown under heme starvation conditions [112]. Overexpression of
PUG1 resulted in decreased cellular heme levels and increased proto-
porphyrin IX (PPIX) content in both wild type and heme-deﬁcientstrains. However, heme uptake was not affected in PUG1Δ strain
[112]. Taken together, these data suggest that Pug1 is involved in PPIX
inﬂux and heme efﬂux. The mechanism and components of the yeast
heme uptake system remain unknown.
3.2. Heme transport and detoxiﬁcation in insects
Adult hematophagous arthropods ingest enormous amount of
blood in a single meal [113]. Accordingly, hemoglobin is undoubtedly
the solemajor source of iron for blood-feeding insects. In themosquito
Aedes aegypti, >98% of iron in the insect body and the eggs comes from
heme [114]. However, free heme is toxic to cells because it can cause
lipid peroxidation. To minimize the toxicity of the heme released by
hemoglobin digestion, these insects have evolved efﬁcient strategies
to excrete, transport, and sequester heme.
The ﬁrst defense against free heme occurs in the insect's gut.
According to an inductively coupled plasma mass spectrometry (ICP-
MS) study in A. aegypti, 87% of total ingested heme iron was excreted
by the end of the ﬁrst gonotrophic cycle [114]. In addition, insects have
specialized structures in the gut to sequester and detoxify heme. In the
lumen of the intestine, ferrous heme can be converted into ferric heme
and aggregate into an insoluble structure called hemozoin [115].
Hemozoin has been identiﬁed in the malaria parasite Plasmodium
falciparum, the parasitic worm Schistosomamansoni, the parasitic pro-
tozoan Haemoproteus columbae, and the kissing bug Rhodnius prolixus
[115,116]. In R. prolixus, the hemozoin in the lumen ofmidgut is theﬁrst
defense against toxicity from free heme [117]. Inhibition of hemozoin
formation by chloroquine leads to increased levels of free heme and
increased lipid peroxidation [118]. In vitro studies further conﬁrmed
that, compared with free heme, hemozoin generated fewer free radi-
cals, caused less lipid peroxidation, and did not lead to the lysis of red
blood cells [119].
Instead of forming hemozoin, themosquito A. aegypti has a layer of
peritrophic matrix covering the intestinal epithelium. This structure
separates intestinal cells from the food and it has been shown to be as-
sociated with high levels of heme after feeding [120]. Devenport et al.
identiﬁed a heme-binding protein, A. aegypti intestinal mucin 1, in the
peritrophic matrix that might be one of the major molecules required
for heme sequestration [121].
Heme uptake has been characterized at the cellular level by moni-
toring ﬂuorescent hemoglobin conjugates or heme analogs in Boophilus
microplus. In contrast to most eukaryotes and even the kissing bug
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pathway [117]. Hemoglobin is taken up by specialized digestive
cells in the midgut through receptor-mediated endocytosis [122].
After the endosomes fuse with primary lysosomes, hemoglobin is
degraded [123]. The released heme is sequestered in specialized in-
tracellular membrane-bound organelles called hemosomes [113,122].
Hemosomes provide a sequestration mechanism for heme and prevent
it from forming free radicals. After absorption, a fraction of heme in the
digestive cells is translocated into the open circulatory system hemo-
coel. It has been shown that several heme-binding lipoproteins may
play a role in the transport and sequestration of heme in the hemo-
lymph. The major hemolymph protein in B. microplus has been charac-
terized as a heme lipoprotein (HeLp). The gene encoding HeLp is
expressed in both male and female ticks after host-attachment and
blood feeding [124]. The protein contains two molecules of heme and
has the capacity to bind six more heme molecules [118]. By injecting
HeLp labeled with 55Fe–heme into the hemocoel, a quick drop of the
radioactivity in hemolymph and a simultaneous increase of 55Fe–
heme within oocytes were observed, suggesting that HeLp might play
a role in delivering heme across tissues [118]. In the American dog
tick Dermacentor variabilis the homolog of HeLp, hemolymph carrier
protein (CP), is also the major hemolymph protein and has been
suggested to play a role in sequestering heme [124–126]. In vitro assays
indicated that HeLp/CP-bound heme induced less oxidative damage to
phospholipids than free heme [127]. These data suggest that HeLp/CP
may be involved in the sequestration and transport of heme.
In ticks and other insects, the major yolk protein vitellogenin has
heme-binding activity. Binding of heme by vitellogenin strongly
inhibited heme-induced lipid peroxidation [119]. After blood feeding,
vitellogenin is primarily produced in the fat body and midgut of fe-
male ticks and is then transferred to developing oocytes [126,128].
Therefore, insect vitellogenin may play a role in transferring heme
and other nutrients to eggs [119,126]. In the egg bound heme is re-
leased when vitellogenin is degraded by endopeptidases such as
vitellin-degrading cysteine endopeptidase, Boophilus yolk cathepsin
and tick heme-binding aspartic proteinase [129,130]. Besides HeLp/
CP and vitellogenin, other proteins such as Rhodnius heme-binding
protein may bind heme and decrease toxicity of free heme in insect
hemolymph [131,132].
3.3. Cellular heme transport in animals
3.3.1. Heme import
It has been long thought that duodenal enterocytes internalize
heme through a receptor-mediated endocytic pathway. Existence of
heme receptors or heme uptake proteins has been shown in the
microvilli of upper small intestine, cultured enterocytes and non-
intestinal cells [133,134]. In a search for putative heme transporters
HRG-1 (Heme‐Responsive Gene-1, systematically named solute carrier
48A1, SLC48A1) was identiﬁed in a screen for genes regulated by heme
in the roundworm Caenorhabditis elegans [135]. This worm is a heme
auxotroph and must, therefore, absorb heme from the environment
and transport it throughout the organism [136]. This nutritional re-
quirement for hemenegates several of the variables, including feedbackTable 1
Heme/porphyrin transporters.
Protein name Proposed function
HRG-1 (SLC48A1) Transport heme
FLVCR (MFSD7B) Export heme
PCFT (formerly HCP1) Import heme?
ABCG2 (BCRP) Export heme
ABCB6 Transport coproporphyrinogen III
ABC-me (M-ABC2/ABCB10) Transport heme intermediates
SLC25A38 Transport glycine and ALA
Pug1p Exports heme and imports PPIX in yeastregulation of heme biosynthesis and non-heme porphyrin transport,
that have historically confounded the mammalian heme transport
ﬁeld. In worms, the HRG proteins hrg-1 and hrg-4 are transmembrane
permeases and depletion of either one disrupts heme sensing and
leads to abnormal responses to heme analogs [135] (Table 1).
Transient knockdown of the zebraﬁsh ortholog, hrg-1, leads to pro-
found erythropoietic defects and ectopic expression of hrg-1 inmurine
erythroleukemia (MEL) cells leads to accumulation of heme analogs
[135]. In addition, heme-dependent transport across the plasma
membrane was observed in Xenopus oocytes expressing worm and
human hrg-1. Only one hrg-1 gene is present in the human genome,
whereas worms have three additional hrg-1 paralogs [137]. This indi-
cates that worms might have evolved redundant heme acquisition
pathways since they lack the ability to synthesize heme.
HRG-1 interacts with heme in a low pH-dependent manner,
suggesting that it may function in relatively acidicmicroenvironments
such as the endolysosome [135]. HRG-1 has been shown to interact
with the c subunit of the vacuolar proton ATPase (V-ATPase) pump
and enhances endosomal acidiﬁcation [138]. It is important to note
that the directionality of heme import from the plasma membrane is
topologically identical to heme import from an intracellular vesicular
compartment as heme still travels from the exoplasmic space into
the cytoplasm.
Human HRG-1 mRNA is highly expressed in the brain, kidney,
heart and skeletal muscle and moderately expressed in the liver,
lung, placenta and small intestine [135]. HRG-1 was also recently
identiﬁed as a target of the heme-dependent transcription factor
BACH1 in microarray expression analysis and ChIP-Seq experiments,
further reinforcing its potential relevance to heme metabolism in
mammalian cells [139]. Bach1 is a basic leucine zipper transcription
factor shown to bind heme [140]. Bach1-Maf heterodimers bind to
Maf recognition elements (MAREs) and repress the expression of tar-
get genes such as globins and heme oxygenase 1 (HO-1) [140–142].
Heme can interact with Bach1 and de-repress transcription. Mecha-
nistic studies using a yeast system suggest that the heme is trans-
located across membranes by human and worm HRG-1 proteins by
conserved amino acids positioned on the exoplasmic, cytoplasmic,
and transmembrane regions [137]. Thus, given HRG1's 1) ability to
transport heme, 2) regulation of synthesis by heme in worms and
BACH1 in mammalian cells, 3) distribution in cell types relevant to
heme and iron metabolism, and 4) localization to endolysosomes,
along with the anemic phenotype of the zebraﬁsh knockdown, and
heme transport in MEL cells and Xenopus oocytes, one would predict
that HRG1 is a compelling candidate for a heme transporter relevant
to macrophage, intestinal and red blood cell heme metabolism.3.3.2. Heme export
The existence of a heme exporter has been speculated for two rea-
sons: 1) efﬂux may be one of the main mechanisms for heme detox-
iﬁcation, since the accumulation of excess heme is highly toxic to
the cells; and 2) efﬂux may facilitate intercellular heme transfer and
heme iron recycling. For example, when macrophages phagocytose
senescent red blood cells and degrade hemoglobin to release heme,Location of function Reference
Vesicles [135]
RBC plasma membrane [144]
Plasma membrane [152,153]
RBC plasma membrane [148]
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iron [143].
One proposed heme exporter is FLVCR (FLVCR1) which belongs to
the major facilitator superfamily [144]. Suppression of FLVCR by the
virus FLV-C in feline embryonic ﬁbroblasts resulted in signiﬁcantly in-
creased cellular heme content, while ectopic expression of FLVCR in
renal epithelial cells reduced the intracellular heme levels [144]. This
result was further conﬁrmed by heme export assays using a ﬂuores-
cent heme analog and 55Fe–heme in renal epithelial and K562 cells.
FLVCR is highly expressed in hematopoietic cells, and heme efﬂuxme-
diated by FLVCR is essential for erythroid differentiation [144,145].
Cats infected with FLV-C developed pure red cell aplasia in which ery-
throid progenitor cells failed to mature from burst-forming units into
the colony-forming-units erythroid cells. No erythropoiesis was ob-
served in FLVCR knock-out mice, and these mice died at mid-gestation
[146]. Deletion of FLVCR also perturbed the heme efﬂux from macro-
phages and therefore blocked the recycling of heme and iron from
senescent red blood cells [146].
Is the mechanism for heme transport across membranes by HRG-
1-related proteins also shared by FLVCR? A recent report showed that
FLVCR2 imported heme in mammalian cells and may be the basis for
the vascular defect in Fowler Syndrome [147]. Although heme import
by FLVCR2 was not observed in the yeast heme import assays along-
side HRG-1, given the high degree of homology between FLVCR2
and the heme efﬂuxer FLVCR1, it is possible that FLVCR2 may be a
exporting heme via intracellular compartments [137]. Heme export
by FLVCR1 is facilitated by hemopexin which binds to a 69 amino
acid peptide (residues 132–201) residing between two exoplasmic
loops and two transmembrane domains [44]. Given the similarity in
membrane topology and conservation of several strategically placed,
heme-binding ligands in the exoplasmic and cytoplasmic loops be-
tween FLVCR1 and FLVCR2, it is possible that these proteins may
have similar functional mechanisms.
TheABC transporter ABCG2, also named as BCRP,was originally iden-
tiﬁed as a drug resistance protein in breast cancer cells. Krishnamurthy
et al. showed that heme interacts with ABCG2 by using hemin-agarose
pull-down assays [148]. PPIX levels in the erythrocytes of ABCG2-null
mice were ten times higher than those in wild type mice [149]
suggesting that ABCG2might function as an exporter for porphyrin com-
pounds. However, no evidence has directly conﬁrmed that ABCG2 can
export heme (see Contradictions below).
3.4. Intracellular heme transport
Whether synthesized within cells or taken up from the environ-
ment, heme in all eukaryotic cells has to be translocated across mem-
brane barriers for either storage and sequestration, or utilization and
incorporation into hemoproteins. The molecules and the mechanisms
involved in intracellular heme trafﬁcking remain poorly understood.
ABCB6 is postulated to play a role in heme transport between mito-
chondria and the cytoplasm. ABCB6 was initially identiﬁed as a mam-
malian ortholog for yeast ATM1, a mitochondrial iron transporter
important for Fe–S cluster biogenesis [150]. However, Krishnamurthy
et al. proposed that ABCB6 was more likely a porphyrin/heme trans-
porter in mitochondria [94]. In cells expressing ABCB6, 55Fe–heme
was readily transported into mitochondria from the cytoplasm in an
energy-dependent manner. The physiological signiﬁcance of a mito-
chondrial heme importer is of question given that the mitochondrion
is the site of the terminal steps of heme synthesis. Another tetrapyr-
role compound, coproporphyrin III, competed with ABCB6 for heme
binding and inhibited heme uptake into mitochondria. Its puzzling
that ABCB6 is present in the C. elegans genome even though worms
do not synthesize heme implying that the true substrate for ABCB6
is still unclear.
More recently, two molecular weight forms of ABCB6 of 79 kDa
and 104 kDa were identiﬁed [151]. Using speciﬁc ABCB6 antibodies,it was shown that while the light form localized to the mitochondrial
outer membrane, the heavy form predominantly resided on the plas-
ma membrane. Overexpression of the plasma membrane form of
ABCB6 reduced the cellular accumulation of another tetrapyrrolic
compound pheophorbide A but not heme. It is possible that the two
ABCB6 forms have distinct functions at different sub-cellular locations,
but further studies are required to pinpoint their physiological roles in
the cell.
3.5. Contradictions
Heme carrier protein (HCP1) was initially identiﬁed from a sup-
pression subtractive hybridization screen using hypotransferrinemic
mice [152]. Expression of HCP1 in Xenopus oocytes and HeLa cells
resulted in 2–3 fold increase in heme uptake with an apparent Km
of 125 μM [152]. However, HCP1 was eventually demonstrated to be
essential for folate transport in the intestine when it was found to
be mutated in patients with congenital folate deﬁciency; HCP1 has a
high afﬁnity for folate (Km ~1.3 μM at pH 5.5) [153]. Whether Hcp1
also contributes to the absorption of heme in the intestine is uncer-
tain at this time [154].
Although BCRP can export heme from cells, BCRP has broad sub-
strate speciﬁcity and can mediate the efﬂux of a large number of
natural and unnatural substrates, and for that reason has been called
a “multidrug resistance” protein [148]. Furthermore, null alleles in
BCRP in humans result in the “Junior” blood system group that has
no apparent clinical phenotype other than transfusion incompatibility
[155]. Likewise, humans with null mutations in ABCB6 have no appar-
ent defects in erythropoiesis but instead produce a new blood group
system named Langereis, suggesting that at least a portion of ABCB6
resides on the plasma membrane of red blood cells [155]. Further-
more, an L811V allele in humans causes ocular coloboma, a develop-
mental defect in the closure of the optic ﬁssure [156]. Although
genetic experiments inmice clearly reveal a hematological defect con-
sistent with the role for FLVCR1 as a heme transporter, recent work
describes a mitochondrial isoform of FLVCR1 that may mediate heme
export from mitochondria into the cytoplasm, suggesting that the
FLVCR1 null phenotype may be due to cytosolic heme deﬁciency, not
accumulation [157].
3.6. Heme transfer between organelles
Just as multiprotein assemblies, for example between CPOX, PPOX,
and FECH, may form to facilitate transport of intermediates during
heme biosynthesis, similar complexes may play a role in exporting
heme from the mitochondrial matrix. The dynamin-like protein
(DLP) mitoﬁlin has been shown to tether the cristae-folds of the
inner mitochondrial membrane to the outer membrane, establishing
the appropriate mitochondrial morphology [158,159]. These contacts
between the IM and OMwould serve as favorable location for the pro-
posed CPOX–PPOX–FECH complex, as well as for proteins regulating
the mobilization of heme out of the mitochondria.
Delivery of iron-loaded transferrin to themitochondria has been ob-
served, implying contiguity between mitochondria and the endocytic
pathway [63]. Conversely, vesicles derived from mitochondrial mem-
branes (MDV) have been shown to carry selected cargo to peroxisomes
and lysosomes [160–162]. These observations hint at the possibility that
heme may be carried out of the mitochondria in MDVs. This would
allow highly regulated transport of heme to target compartments, all
the while shielding the cytoplasm from potentially cytotoxic heme.
Recent studies have also alluded to physical connections between
the ER and mitochondria, raising the possibility that mitochondrial
components can directly move into the ER. Firstly, the yeast proteins
Mmm1, Mdm10, Mdm12, and Mdm34 have been identiﬁed in a com-
plex that tethers mitochondria to the ER membrane [163]. This ER–
Mitochondria Encounter Structure (ERMES) has been hypothesized
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mitochondria [164–167]. Secondly, the dynamin-like GTPasemitofusin,
originally known for its role in mitochondrial fusion and ﬁssion, has
been shown to fuse the ER and outer mitochondrial membrane at spe-
ciﬁc contact points [158,159]. After crossing the inner mitochondrial
membrane using an as-yet-unknown mechanism, heme would be
able tomove directly into the ER lumen at these contact points between
the two organelles.
3.7. Heme binding proteins
Free hemehas peroxidase activity and the iron in heme can generate
reactive oxygen species through Fenton reactions. In addition, as a small
lipophilic molecule, free heme can easily intercalate with, and disrupt
the lipid bilayers of cell membranes. Therefore, heme-binding proteins
or heme chaperones may be required to prevent the toxicity associated
with free heme. The heme-binding proteins may function to sequester
or transport heme (Table 2).
3.8. Cytoplasmic heme binding proteins
Glutathione S-transferases (GSTs) catalyze the conjugation of glu-
tathione to various electrophilic substrates and play essential roles in
xenobiotic detoxiﬁcation. Besides their enzymatic functions, GSTs
have also been known for their ability to bind a variety of ligands in
the cytoplasm. In fact, GSTs were ﬁrst identiﬁed in mammalian liver
as “ligandins” that can selectively bind steroids, bilirubin and organic
anions [168]. Subsequent studies showed that GSTs interact with
heme and porphyrins [169–171].
In malaria parasites and helminths, GSTs are highly abundant in
the cytoplasm. A GST from P. falciparum (Pf-GST) is capable of inter-
acting with heme [172]. This Pf-GST was subsequently shown to con-
tain both high- and low-afﬁnity heme binding sites [173]. In the
rodent malaria parasite, Plasmodium berghei, heme but not PPIX can
inhibit GST activities [174]. Furthermore, an inverse correlation be-
tween heme levels and GST activities has been shown both in vitro
and in P. berghei [174,175]. Brophy's group discovered a novel GST
from the blood-feeding helminth Haemonchus contortus (Hc-GST-1)
that is able to interact with heme [176]. The homologous protein in
Ancylostoma caninum, Ac-GST-1, also binds heme [177]. These GSTs
have been postulated to play critical roles in the detoxiﬁcation and
transport of heme [172,176,178].
A murine 22 kDa protein, p22HBP, was identiﬁed as a cytosolic
heme-binding protein ubiquitously expressed in various tissues with
high levels in the liver [65]. In mouse erythroleukemia (MEL) cells,
p22HBP was induced during erythroid differentiation and knock-
down of the gene resulted in reduced heme content in MEL cells. InTable 2
Heme binding proteins.
Protein name Proposed function Lo
HRG-3 Bind heme Ex
HRG-2 Bind heme Hy
FABP Bind heme/tetrapyrroles Cy
GST Bind heme/tetrapyrroles Cy
HBP23 Bind heme/tetrapyrroles Cy
SOUL/p22HBP family Bind heme/tetrapyrroles Cy
Haptoglobin Bind extracellular Hb Blo
Hemopexin Bind extracellular heme Blo
HDL and LDL Bind extracellular heme Blo
HeLp Bind extracellular heme He
Vitellogenin Bind heme for heme transfer Ex
GAPDH Heme insertion into iNOS Cy
HSP90 Heme insertion into iNOS/nNOS Cy
Cyc2p Heme reductase M
Dap1p/PGRMC1 Heme transfer to cytochrome P450 ER
Dcytb Ferric reductase En
Human serum albumin Bind extracellular heme Bloaddition to heme, themouse and human protein binds other porphyrin
compounds such as PPIX [65,71,104]. It was revealed by a structural
analysis that a hydrophobic cleft was responsible for tetrapyrrole bind-
ing in p22HBP [104]. Two homologous proteins in Arabidopsis thaliana,
cHBP1 and cHBP2, were also found to bind tetrapyrroles reversibly in
vitro [179]. These two HBPs may play similar roles in different plant tis-
sues since cHBP1 is highly expressed in leaveswhereas the highest level
of cHBP2 is detected in roots [179]. The murine protein SOUL has 27%
sequence identity to p22HBP. Early studies on SOUL reported it to be a
dimer in the absence of heme and a hexamer in the presence of heme
[180,181]. More recently, however, crystal structure, surface plasmon
resonance and NMR studies by Ambrosi et al. [182] clearly demon-
strated that SOUL is a monomer and that it does not bind heme. SOUL
was shown to possess a Bcl-2 homology 3 (BH3) domain and current
evidence suggests that it plays a role in apoptosis and/or oxidative
stress and not heme trafﬁcking.
HBP23 belongs to the peroxiredoxin family of peroxidases and is
also called mouse stress-inducible 23 kDa protein or proliferation-
associated gene product. The protein was originally identiﬁed from
rat liver using chromatography on hemin-agarose and was shown to
have a high binding afﬁnity for heme [183]. On the protein surface,
two hydrophobic regions, both containing histidine residues, might
be responsible for heme binding [184]. The protein is highly expressed
in the cytoplasm of the liver and also present in kidney, spleen, small
intestine, and heart. Heme, PPIX, and other metalloporphyrins are able
to stimulate HBP23 expression in rat primary hepatocytes [185]. Fur-
thermore, incubation of rat liver HBP23 with heme inhibited its antiox-
idant activity [186].
Nitric oxide synthases (NOS) are soluble hemoproteins which cat-
alytically convert L-arginine to citrulline and nitric oxide (NO). Mam-
mals have three NOS — endothelial (eNOS), inducible (iNOS), and
neuronal (nNOS). NOS form homodimers and its activity is dependent
on heme insertion. Studies from the Stuehr group have suggested that
NO blocks heme insertion into extramitochondrial hemoproteins
without changes in intracellular heme levels [187,188]. Interestingly,
heme insertion into iNOS has been reported to be mediated by
GAPDH, a glycolytic enzyme [189]. Although GAPDH has been tradi-
tionally implicated as a cytoplasmic housekeeping protein, potential
new roles are emerging for this protein in the nucleus (DNA repair),
cytoplasm (membrane fusion and cytoskeletal remodeling) and mito-
chondria (cell survival) [190]. It has been reported that heme inser-
tion into NOS is facilitated by the molecular chaperone HSP90; the
ATPase activity of HSP90 in the presence of as of yet unidentiﬁed
heme chaperone, postulated to be GAPDH, is essential for heme inser-
tion into apo-iNOS [191], or nNOS [192]. However, it's important to
note that HSP90 is a highly abundant (1–2% of total cellular protein)
and promiscuous protein that localizes to the nucleus, mitochondriacation of function Reference
tracellular in C. elegans [215]








molymph in insects [118,124]




but also detected in cytosol, PM and secretory pathway [240,241,245]
terocytes [231]
od [211]
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of client proteins with low stability or exposed hydrophobic surfaces
[193].
Fatty acid binding proteins are known to be able to bind heme
[194,195]. However, the cellular functions of heme-binding activities
in these cytosolic proteins are still unclear.
3.9. Extracellular heme binding proteins
Heme and hemoglobin are released into the plasma during the de-
struction of senescent erythrocytes and enucleation of erythroblasts.
Under pathological conditions such as hemoglobinopathies, trauma,
and infections, more severe intravascular hemolysis is induced. To
prevent tissues from experiencing heme toxicity and to increase the
recycling of heme iron, mammalian cells secrete speciﬁc molecules
to bind heme and hemoglobin in the circulation.
Haptoglobin (hapto- “bind to”), primarily synthesized by hepato-
cytes, is a plasma glycoprotein with hemoglobin-binding capacity.
There are three major subtypes of haptoglobin [196] all of which can
form soluble complexes in an equimolar ratio with hemoglobin dimers
(Kd ~10−12 M) [197–199]. Haptoglobin–hemoglobin complexes bind
to the CD163 receptor on the surface of monocytes and macrophages
and these complexes are subsequently endocytosed [200]. Receptors
for the haptoglobin–hemoglobin complex also exist in hepatocytes
and hepatoma cell lines [201,202]. After entering the cells, iron is re-
leased by heme degradation, whereas the remaining protein complex
is degraded by lysosomes [203–205]. Physiologically, binding of hapto-
globin reduces the loss of hemoglobin and heme iron [205,206].
Hemopexin is a heme-binding plasma protein that binds heme
with high afﬁnity (Kd ~10−13 M) [207]. Hemopexin–heme complexes
are endocytosed in response to the binding with LRP/CD91 (LDL
receptor-related protein, or CD91) in a variety of cells including hepa-
tocytes, macrophages, and syncytiotrophoblasts [208]. Unlike hapto-
globin, hemopexin is recycled back into the circulation after the
release of heme during endocytosis [208,209]. In response to heme
overload, hemopexin null mice exhibited increased oxidative stress
and altered regulation of HO-1 as well as ferritin, suggesting critical
roles of hemopexin in heme detoxiﬁcation [210].
Human serum albumin (HSA), a 66 kDa protein, binds a wide vari-
ety of proteins as well as heme (Kd ~10−8 M) [211,212]. The crystal
structure shows that a hydrophobic cleft in one of its three sub-
domains binds heme. Three basic residues at the entrance to this
cleft form charge pair interactions with the propionate side chains of
heme, and the iron in heme is coordinated by a tyrosine residue [213].
Two additional serum proteins, high-density and low-density li-
poproteins, bind heme faster than both hemopexin and HSA with an
afﬁnity that is higher than that of HSA for heme (Kd ~10−11 M)
[211,214]. It is thought that this rapid binding is critical to prevent
damage by heme during the initial release of heme and provides a
buffer period for hemopexin and HSA to steadily but tightly bind
heme. Eventually, hemopexin and HSA remove all but a residual
amount of heme from the lipoproteins [214].
3.10. Intercellular heme transport
Genetic screens in C. elegans identiﬁed over 200 Heme Responsive
Genes (HRGs). Dietary heme is transported into the worm intestine
by membrane-bound permeases, HRG-1 and HRG-4 [135,137]. How-
ever tissues such as muscle, neurons, hypodermal cells, and embryos
are dependent upon intestinal heme to fulﬁll their metabolic require-
ments, so some mechanism for intercellular transport of heme must
exist since C. elegans lacks heme synthesizing capability. Consistent
with this concept HRG-3, a peptide secreted by the mother's intestine,
functions to transportmaternal heme to developing oocytes and ensures
that sufﬁcient heme is available to sustain embryonic development
[215]. HRG-3 deﬁciency results either in death during embryogenesisor in developmental arrest immediately post hatching — phenotypes
that are fully suppressed by maternal but not zygotic hrg-3 expression.
HRG-3 binds both ferrous and ferric heme with a stoichiometry of two
protomers to one heme [215]. These results imply that HRG-3may func-
tion as an intercellular chaperone tomobilizematernal heme and deliver
it to extra-intestinal tissues and oocytes. However, questions remaining
unanswered are 1) the nature of the internalization mechanism for
HRG-3–heme complex into oocytes, 2) the identity of speciﬁc cell
surface receptors for HRG-3 on extra-intestinal tissues, and 3) themech-
anism and regulation of heme release from HRG-3 within the embryo.
Although an intercellular heme transport system is to be expected
in worms which are heme auxotrophs, an intercellular pathway for
heme distribution may also exist in vertebrates based on the follow-
ing experimental evidence. Firstly, cell culture studies with human
colon-derived Caco-2 cells and mouse macrophages reveal that a por-
tion of heme derived from dietary sources or senescent red blood
cells is released into the blood stream as an intact metalloporphyrin
[143,216]. Secondly, human patients with acute attacks of porphyrias
are administered heme intravenously as an effective therapeutic
treatment which results in lowering the accumulation of heme syn-
thesis intermediates and a concomitant increase in liver heme-
dependent enzyme activities indicating that infused heme can be uti-
lized by peripheral tissues [28,217]. Thirdly, even though knockout of
the heme synthesis pathway inmice is embryonic lethal, homozygous
embryos survive at least till E3.5 suggesting the existence of heme
stores [218,219]. Lastly, zebraﬁsh embryos with loss-of-function mu-
tations in heme synthesis genes can survive from 10 to 25 days post
fertilization, because these embryos may either contain maternal-
derived mRNA for heme synthesis enzymes or directly deposited
maternal heme [114,220]. Together, these results lead us to propose
the existence of a functional intercellular pathway to facilitate the
targeted delivery and redistribution of heme during vertebrate devel-
opment. Consistent with this notion, FLVCR1 and HRG-1 may function
to redistribute heme during organogenesis and development. Indeed,
FLVCR1 is expressed substantially in the yolk sac and placenta, per-
haps to mobilize maternal heme for fetal development [146,221].
3.11. Parasitic worms and heme
Parasitic worms are a major cause of chronic infections in humans,
farm animals and plants. More than a quarter of the world's population
is affected by one or more of the 20 most common parasites including
Ascaris, Ancylostoma, Trichuris and Schistosome [222,223]. In addition,
animal parasites and plant parasites cause enormous economic loss in
agricultural production every year. Traditional drugs are becoming
more andmore ineffective in helminthic control as drug-resistant nem-
atodes are already prevalent in humans and other animals [224,225].
Heme and iron play essential roles in development, reproduction
and pathogenicity of parasitic worms. For example, iron supplement
stimulates the growth of the ﬂuke S. mansoni in vitro [226]. Due to the
fact that free iron is tightly controlled in animal hosts and S. mansoni
ingests huge amount of blood, it is highly possible that these parasites
acquire iron predominantly in the form of heme from the blood [227].
In the hookworm, Ancylostoma ceylanicum, host iron status has been
shown to be a key mediator of pathogenicity. Challenged animal hosts
supplied with iron-restricted diet had a signiﬁcant reduction in the in-
testinal load of worms [228].
In the intestine of the canine hookworm A. caninum, hemoglobin
is degraded by a cascade of proteolytic reactions involving aspartic
proteases (APR-1), cysteine proteases and metalloproteases [229].
Vaccination of dogs with APR-1 to generate neutralizing antibodies
dramatically reduced the hookworm burdens, fecal egg counts, as
well as host blood loss, after challenging with A. caninum larvae [177].
Recently, Rao et al. discovered that parasitic worms including
Strongyloides, Ancylostoma, Haemonchus, Trichuris and Ascaris are un-
able to synthesize heme de novo [136]. Analysis of the genomes for
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such as globins, cytochrome P450s, catalases and guanylate cyclases.
Therefore, worms must have developed an efﬁcient heme uptake sys-
tem to meet their nutritional requirement and a heme storage system
to store essential but cytotoxic heme. In addition, since none of the
cells have the ability to synthesize heme, an intercellular heme trans-
port system is required to mobilize heme from intestinal cells – the
site of absorption – to other cell types including neurons, muscles,
hypodermis, and developing embryos. Thus, worm-speciﬁc molecules
involved in heme homeostasis, especially in heme uptake, could be
potential drug targets for helminthic control.
3.12. Heme reductases
Metalloreductases have been shown to be essential for the uptake of
metals. For example, duodenal cytochrome b (Dcytb) and six trans-
membrane epithelial antigen of the prostate 3 (Steap3) were identiﬁed
as ferric reductases that were associated with efﬁcient iron uptake into
cells [230–232]. Subsequent studies found that Dcytb and proteins in
the Steap family also function as cupric reductases [233,234].
Studies have indicated that hemin (heme with an oxidized iron
atom) has to be reduced for its covalent attachment to apocytochrome
c [235,236]. The Cyc2p protein is postulated to function as a heme re-
ductase, using NAD(P)H as a cofactor, in the intermembrane space
(IMS) of the yeast mitochondria [237,238]. Cyc2p functions in concert
with cytochrome heme lyases for covalent attachment of heme to
apocytochromes c and c1. Given that heme synthesis occurs within the
mitochondrial matrix and FECH produces reduced heme, the model
for heme reduction in the IMS by Cyc2p would suggest that the heme
is oxidized in that compartment by an unknown mechanism.
In Gram-negative bacteria, cytochrome c synthetase CcmF was re-
cently proposed to function as a quinol:heme oxidoreductase [236]. In
addition, the lipocalin α1-microglobulin also has the ability to reduce
hemin in cytochrome c and methemoglobin [216]. However, plasma
membrane-associated hemin reductases that might play a role in
hemin uptake remain elusive. Another possible candidate heme re-
ductase is HRG-2, a type Ia membrane protein, which localizes to the
ER in the C. elegans hypodermis [239]. Worms deﬁcient in HRG-2
show abnormal distribution of soluble hemoproteins and altered
gene expression of several cytochromes. However, direct evidence
for a reductase activity was not demonstrated because of the inability
to isolate puriﬁed protein. Measurement of heme reductase activity in
crude cell extracts is nontrivial and fraught with technical hindrances,
not the least of which are identifying the source of reducing power
(enzyme and cofactor) or the nature of potential heme donor and/or
acceptor. Nevertheless, the topology of HRG-2 is identical to that of mi-
crosomal cytochrome P450s and is reminiscent of the heme-binding
protein Dap1p in yeast and its human ortholog PGRMC1 which can in-
teract with cytochrome P450s and increase their activities by an as of
yet poorly characterized heme delivery system [240,241].
4. Conclusion
Because of its brilliant color and near ubiquitous presence in biology,
heme has long been an object of scientiﬁc inquiry. The relationship be-
tween clinical symptoms of a disease and speciﬁc biochemical defects
was ﬁrst recognized with the porphyrias. The identiﬁcation and charac-
terization of enzymes of the heme biosynthetic pathway have a history
of over 60 years, yet information on the intracellular movement of
heme and heme precursors along with how heme is eventually assem-
bled into hemoproteins is lacking. Interestingly this ﬁeld now seems to
be following the lead set by researchers who focus on metal transport
over the past two decades and deﬁned components necessary for trans-
port and sequestration of physiologically relevant metals. With the
availability of advanced genetic, biophysical, microscopic and biochem-
ical tools it is hoped that the pathways and molecules in porphyrin andheme trafﬁcking are soon identiﬁed and result in a holistic model for
porphyrin and metal metabolism.
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